Multidisciplinary Primary Rehabilitation Care for Patients With Chronic Musculoskeletal Pain
MPRC_CMP
1 other identifier
interventional
1,400
1 country
5
Brief Summary
Rationale: A great variability in treatment contents, ways of collaboration between healthcare professionals, and evaluation methods for the treatment in chronic musculoskeletal pain (CMP), exists. Currently, multidisciplinary diagnostics, pain education and treatment in primary care, in collaboration with secondary care, especially with a biopsychosocial approach, is barely or not organized for patients having CMP. Objective: The aim of this study is to gain insight into the feasibility, health care and societal costs, effects regarding the patients' functioning and participation and perceived quality of care of the multidisciplinary primary rehabilitation care (MPRC) for different organization structures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2022
Longer than P75 for not_applicable
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2022
CompletedFirst Submitted
Initial submission to the registry
July 14, 2022
CompletedFirst Posted
Study publicly available on registry
September 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2026
CompletedSeptember 7, 2022
September 1, 2022
4 years
July 14, 2022
September 6, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Changes in perceived level of disability
Measured with the Pain Disability Index (PDI) questionnaire
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Changes in physical quality of life
Measured with the Physical Component Scale (PCS) of the SF-12 questionnaire
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Secondary Outcomes (9)
Changes in health-related productivity losses
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Changes in health care consumption
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Changes in work ability
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Changes in self efficacy
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
Changes in life participation
At the start of the treatment (the diagnostic phase) (T0), at three months (T1); at nine months (T2) and at fifteen months (T3).
- +4 more secondary outcomes
Study Arms (1)
Patients with musculoskeletal pain
EXPERIMENTALPatients with musculoskeletal pain
Interventions
As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
Eligibility Criteria
You may qualify if:
- age≥18 years
- musculoskeletal pain
- duration of musculoskeletal pain ≥ 3 months
- monodisciplinary primary care is completed
You may not qualify if:
- previous experiences with treatment in multidisciplinary secondary or tertiary care
- Co-morbidities limiting to complete the treatment program within the preset time
- BMI ≥ 35
- present addiction or other psychiatric problems
- inadequate understanding of the Dutch language.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Maastricht University Medical Centerlead
- Zilveren Kruiscollaborator
- Zorgverzekeraar CZcollaborator
- Zorgverzekeraar Menziscollaborator
- Rotterdam University of Applied Sciencescollaborator
Study Sites (5)
OCA
Eindhoven, 5652NP, Netherlands
Activos
Goes, 4461LT, Netherlands
Belife
Rotterdam, 3062MA, Netherlands
Eenplus
Velp, 6881LD, Netherlands
CIR
Zwolle, 8025AX, Netherlands
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 14, 2022
First Posted
September 7, 2022
Study Start
February 1, 2022
Primary Completion
February 1, 2026
Study Completion
February 1, 2026
Last Updated
September 7, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share